...
首页> 外文期刊>Biochemical Pharmacology >TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma
【24h】

TMEM16A-inhibitor loaded pH-responsive nanoparticles: A novel dual-targeting antitumor therapy for lung adenocarcinoma

机译:TMEM16A-抑制剂负载pH-响应纳米粒子:一种用于肺腺癌的新型双靶向抗肿瘤疗法

获取原文
获取原文并翻译 | 示例
           

摘要

To overcome the adverse effects of conventional chemotherapy for cancers, various nanoparticles based drug delivery systems have been developed. However, nanoparticles delivering drugs directly to kill tumor cells still faced with challenges, because tumors possessed adopt complex mechanism to resist damages, which compromised the therapeutic efficacy. TMEM16A/CaCCs (Calcium activates chloride channels) has been identified to be overexpressed in lung adenocarcinoma which can serve as a novel tumor specific drug target in our previous work. Here, we developed a novel dual-targeted antitumor strategy via designing a novel nano-assembled, pH-sensitive drug-delivery system loading with specific inhibitors of TMEM16A against lung adenocarcinoma. For validation, we assayed the novel dual-targeting therapy on xenograft mouse model which exhibited significant antitumor activity and not affect mouse body weight. The dual targeting therapy accomplished in this study will shed light on the development of advanced antitumor strategy.
机译:为了克服常规化疗对癌症的不利影响,已经开发了各种基于纳米颗粒的药物递送系统。然而,纳米颗粒直接递送药物以杀死肿瘤细胞仍面临挑战,因为肿瘤具有抗拒损害的复杂机制,这损害了治疗效果。已经鉴定TMEM16A / CACC(钙激活氯化钙通道)在肺腺癌中过表达,可以作为我们之前的工作中的新型肿瘤特异性药物目标。在这里,我们通过设计具有特异性抑制剂的TMEM16A对肺腺癌的特异性抑制剂的新型纳米组装,pH敏感的药物输送系统负荷开发了一种新的双重针对性的抗肿瘤策略。为了验证,我们在表现出显着的抗肿瘤活性并且不影响小鼠体重的异种移植小鼠模型中进行了新型双靶向治疗。本研究中完成的双重靶向疗法将揭示先进的抗询问策略的发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号